Seeking Alpha

Ranbaxy Laboratories Limited ADR (RBXLY)

- Grey Market
  • Apr. 7, 2014, 3:32 AM
    • Sun Pharmaceutical Industries has agreed to acquire fellow Indian company Ranbaxy Laboratories (RBXLY) for $3.2B in an all-stock deal that will create the world's fifth-largest generic-drug maker. Including the debt, the transaction is worth $4B.
    • The merger combines two firms that have had problems with quality issues. Ranbaxy, which is owned by Japan's Daiichi Sankyo (DSKYF), is banned from selling ingredients to the U.S., while Sun's Karkhadi facility is also not allowed to export products to the U.S. (PR)
    | 1 Comment
Visit Seeking Alpha's
RBXLY vs. ETF Alternatives
Company Description
Currently, there's no company description for RBXLY.
Country: India